Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial
Adverse event studies of favipiravir used to treat COVID-19 have been ongoing since it was established as a treatment option. A better understanding of the side effects of favipiravir from recent studies is important for developing and assessing the introduction of effective treatments for COVID-19
The role of fever in COVID-19 has not been studied in large studies. In our review of the literature, only two studies have related the ambient temperature or fever to the outcomes of the COVID-19 patients. In a non-peer-reviewed observational study, the high ambient temperature was correlated with decreased mortality in COVID-19 patients in Wuhan and Hubei provinces; however, no data on …
The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the researchers to strive to develop drugs or vaccines to prevent or halt the progression of this ailment. To hasten the treatment process, repurposed drugs are being evaluated. Favipiravir is one such oral drug that was approved for new and reemerging pandemic influenza in Japan in 2014 and has shown potent in vitro ac…